Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map
Authors' conclusion
This umbrella review identified significant beneficial associations between pharmacotherapies and anthropometric measures, lipid profile, blood pressure, glycemic profile, and quality-of-life outcomes in individuals with overweight or obesity. In addition, the umbrella review highlighted safety considerations. The findings affirm the efficacy of the six pharmacotherapies in promoting weight loss in this demographic. Further clinical trials with long-term follow-up are essential to evaluate the effects of these pharmacotherapies on clinical outcomes, including cancer, cardiovascular events, and mortality.
Study context
- Population
- Individuals with overweight or obesity; Meta-analyses (MAs) of randomized clinical trials (RCTs) searched in PubMed, Embase, Cochrane Library and Web of Science to January 202416 MAs · 235 RCTs
- Comparison
- Six weight management pharmacotherapies
- Outcome
- Associations between the six pharmacotherapies and health outcomes
Methodological detailsrandom-effects model, AMSTAR 2 quality assessment
- Random-effects model
- AMSTAR 2 quality assessment
Pooled result
As reported in the abstract
Unique associations described
115
Statistically significant associations with beneficial outcomes (body weight, weight loss, waist circumference, BMI, total cholesterol, TG, LDL-C, HDL-C, blood pressure, glycemic profile)
101
88%
Further pooled results
- Methodological quality of included MAs requires improvement
Safety
- Notable adverse events (AEs) associated with liraglutide, naltrexone/bupropion, semaglutide and orlistat
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →